TSR-022, a humanized anti-TIM3 IgG4 monoclonal antibody for solid malignancies like NSCLC, HCC, and melanoma, has shown dose-dependent clinical activity in a cohort of 202 NSCLC patients resistant to PD-1/PD-L1 antibodies, particularly when administered with a fixed dose of TSR-042, a PD-1 targeting antibody, without encountering any dose-limiting toxicities [149]. Here, PDCD1 is linked to melanoma.